louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03322176: Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing
Official title: Medical Provider Experience Assessment Healthcare Decisions Post-Testing, Risk-Reducing, and Preventative Strategies Using LYNCH Genetic Testing
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Colon Cancer
Endometrial Cancer
Lead sponsor: Data Collection Analysis Business Management
Sponsor class: OTHER
Collaborators: name: PAS Research Services
First posted: 2017-10-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: collecting data and reviewing the Principal Investigators' (P.I.) Standard Operating Procedures (SOP) on Lynch genetic testing and changes made to their specific SOP.

Brief summary: Increase surveillance for LYNCH Syndrome

Detailed description: The purpose of this minimal risk, observational survey is to increase surveillance for Lynch Syndrome (hereditary non-polyposis colon cancer), Colorectal, and Endometrial cancer, also to determine targeted risk-reducing and preventative strategies.

Eligibility criteria: Inclusion Criteria:

* Must be a Medical Practitioner

  * Medical Doctor (MD)
  * Doctor of Osteopathic (DO)
  * Physician Assistant (PA)
  * Advanced Practice Registered Nurse (APRN)
  * Nurse Practitioner (NP)
* Must have a current standard operating procedure that includes obtaining/reviewing medical history and family medical history.

Exclusion Criteria:

* Government-funded insurance data cannot be included in the study.

Primary outcomes:
measure: Provider Structures and Processes
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Land O' Lakes
country: United States
facility: DCABM
state: Florida
Study officials:
References:
Clinical trial NCT06236776: AWARE Registry: Wearable ECG in Structural Heart Interventions
Official title: Arrhythmia Assessment in Structural Cardiac Interventions Using Wearable ECG Monitoring: AWARE Registry
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atrial Septal Defect
Patent Foramen Ovale
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2024-02-01
Enrollment: 150
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who scheduled to perform percutaneous device closure for atrial septal defect or patent foramen ovale

Brief summary: This study is a multi-center (Sinchon Severance hospital / Gangnam Severance hospital), prospective cohort observational study to patients who had undergone structural heart intervention including device closure for secundum type atrial septal defect or Patent foramen ovale. Transthoracic echocardiography will be performed before the procedure, immediately after, and at 6, 18, 30 months after the procedure. Wearable ECG monitoring (\> 3 days) will be performed before the procedure or immediately after procedure. Demographic, laboratory, hemodynamic data during procedure, and non-invasive imaging dat are obtained.


Eligibility criteria: Inclusion Criteria:

* Adult ≥ 19 year-old
* Patients who scheduled to perform percutaneous device closure for atrial septal defect or patent foramen ovale
* Patients provided with the written, informed consent to participate in this study

Exclusion Criteria:

* Patients who had paroxysmal, persistent, or chronic AF
* Life expectancy \< 12 months
* Subject who the investigator deems inappropriate to participate in this study

Primary outcomes:
measure: Occurrence of atrial fibrillation
timeFrame: Immediate post-operative
measure: Occurrence of atrial fibrillation
timeFrame: 18 month
measure: Occurrence of atrial fibrillation
timeFrame: 30 month
Secondary outcomes:
measure: All cause-death
timeFrame: Immediate post-operative, 18 month , 30 month
measure: hospitalization for heart failure
timeFrame: Immediate post-operative, 18 month , 30 month
measure: new atrial fibrillation
timeFrame: Immediate post-operative, 18 month , 30 month
measure: new atrial tachycardia
timeFrame: Immediate post-operative, 18 month , 30 month
measure: high burden of APC/PVC (>15%)
timeFrame: Immediate post-operative, 18 month , 30 month
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine
Study officials:
affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine
name: Iksung Cho
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01862276: Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma
Official title: Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intrahepatic Cholangiocarcinoma
Lead sponsor: Kansai Hepatobiliary Oncology Group
Sponsor class: NETWORK
First posted: 2013-05-24
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who underwent hepatic lobectomy between 2000 and 2010 for intrahepatic cholangiocarcinoma, and did not undergo adjuvant chemotherapy will be included for analysis.

Brief summary: To investigate the prognosis due to presence or absence of bile duct resection in intrahepatic cholangiocarcinoma that require hepatic lobectomy.

Detailed description: The bile duct resection in hepatic lobectomy due to cholangiocarcinoma, mass forming type, is still controversial. We retrospectively evaluated the effect of bile duct resection in this surgery.

Eligibility criteria: Inclusion Criteria:

* Cases of major hepatectomy due to intrahepatic cholangiocarcinoma

Exclusion Criteria:

-

Primary outcomes:
measure: 3-year recurrence-free survival rate
timeFrame: 11 years (2000-2010)
measure: Ratio of local recurrence at the hepatico-duodenal ligament
timeFrame: 11 years
Secondary outcomes:
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Osaka University, Graduate School of Medicine
Study officials:
affiliation: Osaka University Graduate School of Medicine
name: Hiroaki Nagano, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01630876: Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane
Official title: Anatomic and Functional Outcomes of 23-gauge Vitrectomy Combined With Posterior Subtenon Triamcinolone Injection for the Treatment of Idiopathic Epiretinal Membrane
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Epiretinal Membrane
Keywords: Epiretinal membrane
triamcinolone acetonide
Lead sponsor: Yeungnam University College of Medicine
Sponsor class: OTHER
First posted: 2012-06-28
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the anatomical and visual outcomes of patients with idiopathic epiretinal membrane(ERM) treated by vitrectomy and membrane peeling with or without subtenon triamcinolone acetonide injection


Eligibility criteria: Inclusion Criteria:

* 1.The participant must have idiopathic epiretinal membrane 2.The participant must be willing and able to comply with the protocol.

Exclusion Criteria:

* 1. The participant has idiopathic epiretinal membrane with other ocular vascular diseases such as Diabetes retinopathy, BRVO, etc.

  2. The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy.

  3. The participant has had intraocular surgery (including lens replacement surgery).

  4. The participant has a history of (within the last six months), or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).

Primary outcomes:
measure: Changes of best corrected visual acuity and central retinal thickness
timeFrame: 6 months
Secondary outcomes:
measure: Changes in status of ISOS line
timeFrame: 6 months
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Yeungnam University College of Medicine
Study officials:
References:
Clinical trial NCT04683276: ILM Inverted Flap Size in Macular Hole
Official title: Impact of the Inverted Internal Limiting Membrane Flap Diameter on Idiopathic Macular Hole Closure: Comparative Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Idiopathic Macular Hole
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2020-12-24
Enrollment: 42
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the current study, the investigators described the results of a randomized, comparative clinical trial that was conducted to study the impact of the size of internal limiting membrane (ILM) inverted flap on rate and timing of idiopathic macular hole closure.

Detailed description: A prospective randomized comparative study included patients with idiopathic macular hole (MH) attending outpatient clinic.Eligible eyes were divided into 2 groups based on the narrowest diameter of the MH measured by spectral domain optical coherence tomography (SD-OCT). MHs from 250 to 400µm were classified as Medium-sized MHs and MHs \> 400 µm were classified as Large-sized MHs. Within each group, eyes were randomly assigned to either small-flap (1-2DD) or large flap (from \>2 to 4DD).

Eligibility criteria: Inclusion Criteria:

* Eyes with stage 4 idiopathic MHs with a diameter \>250µm on spectral domain optical coherence tomography (SD-OCT)

Exclusion Criteria:

* traumatic MH
* myopic MHs,
* MH secondary to retinal detachment,
* long-standing MH\> 12 months
* previous retinal surgeries
* high myopia with an axial length \> 26.0 mm
* other ocular pathologies interfering with the interpretation of the OCT reports.

Primary outcomes:
measure: rate of macular hole closure
timeFrame: 6 months
Secondary outcomes:
measure: timing of MH closure
timeFrame: 6 months
measure: BCVA
timeFrame: 6 months
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Ophthalmic center
state: Dakahelia
Study officials:
References:
Clinical trial NCT01351376: LLLT Combined With CDT in Breast Cancer-Related Lymphedema
Official title: The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lymphedema
Keywords: Lymphedema, Low Level Laser, Breast Cancer
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2011-05-10
Enrollment: 21
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy (CDT) when compared to CDT treatment alone. The investigators hypothesize that the addition of LLLT to CDT will result in statistically significant improvements and greater long-term benefits as measured by changes in arm volume and quality of life when compared to the benefits of CDT alone for the treatment of breast cancer-related lymphedema.


Eligibility criteria: Inclusion Criteria:

* unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection)
* stage II or III unilateral secondary upper extremity lymphedema (as defined by the International Society of Lymphology)
* girth ≥ 2 cm circumferential difference and/or volume ≥ 200 mL compared to the uninvolved upper extremity at any 4 cm segment
* able to commit to a long term follow-up schedule

Exclusion Criteria:

* active cancer/metastatic cancer
* currently receiving or have plans for adjuvant radiation or chemotherapy
* pregnant
* presence of other extremity lymphedema (primary or secondary)
* pacemaker
* artificial joints in the upper quadrants
* renal failure
* arterial insufficiency
* congestive heart failure
* chronic inflammatory conditions
* history of deep vein thrombosis (DVT) in the lymphedematous upper extremity
* previous treatment with Low Level Laser (regardless of indication)
* medication(s) known to affect body fluid balance
* body mass index (BMI) \> 40 (morbid obesity)

Primary outcomes:
measure: Arm Volume
timeFrame: 13 Months
Secondary outcomes:
measure: Short-Form Health Survey (SF-36)
timeFrame: 13 months
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Clinical Cancer Center
state: New York
city: New York
country: United States
facility: NYU Rusk Institute of Rehabilitation Medicine
state: New York
city: New York
country: United States
facility: Tisch Hospital
state: New York
Study officials:
affiliation: NYU Rusk Institute of Rehabilitation Medicine
name: Teresa Denham, PT, MA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03888976: Cholecystoduodenal Fistula With and Without Gallstone Ileus
Official title: Cholecystoduodenal Fistula With and Without Gallstone Ileus: A Case Series
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gallbladder Diseases
Keywords: Cholecystoduodenal fistula
Gallbladder
Lead sponsor: Tecnologico de Monterrey
Sponsor class: OTHER
First posted: 2019-03-25
Enrollment: 10
Sex: ALL
Minimum age (years): 15
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent surgical resection of cholecystoduodenal fistula

Brief summary: Observative and descriptive study of 10 patients, which were diagnosed with a Cholecystoduodenal fistula, All electronic medical records were retrospectively reviewed.

Detailed description: A cholecystoenteric fistula is an uncommon complication of gallstone disease, although most studies in the English literature concern biliary-enteric fistulas. The aim of this study was to present a case series of patients with a cholecystoduodenal fistula (CDF), with or without gallstone ileus, along with the surgical outcomes.

From 2015 to 2018, 3245 consecutive patients underwent cholecystectomy for gallbladder disease at our institution, of whom 10 were diagnosed with a CDF. All electronic medical records were retrospectively reviewed.

Eligibility criteria: Inclusion Criteria:

* Patients with cholecystoduodenal fistula

Exclusion Criteria:

* Patients with cholecystocolonic fistula or cholecystogastric fistula

Primary outcomes:
measure: Median Age
timeFrame: Feb 01- 2020
measure: Median value of white blood count
timeFrame: Feb 01-2020
measure: Type of surgery performed
timeFrame: Feb 01-2020
measure: Surgical complications
timeFrame: Feb 01-2020
measure: Recovering time
timeFrame: Feb 01-2020
Secondary outcomes:
Other outcomes:
Locations:
city: San Nicolás De Los Garza
country: Mexico
facility: Hospital Metropolitano
state: Nuevo Leon
Study officials:
References:
Clinical trial NCT02705976: Prospective Trial of a Validated Algorithm for Warfarin Dosing
Official title: Prospective Trial of a Validated Algorithm for Warfarin Dosing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anticoagulation
Lead sponsor: Aalborg University Hospital
Sponsor class: OTHER
First posted: 2016-03-11
Enrollment: 211
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to perform a randomized trial comparing the use of the algorithm, with dosing of warfarin in standard manual dosage clinical practice, in a high quality anticoagulant setting (PSM). This is done for safety concerns and to ensure good performance of the algorithm when used in a clinical setup. The results from the study are expected to increase our knowledge of efficacy by using the algorithm in clinical practice.


Eligibility criteria: Inclusion Criteria

* Participants will be those ≥18 years old, must refer to Trombosecenter Aalborg and have to be educated as PSM patient
* Have to be treated for at least 1 month and willing to sign informed consent

Exclusion Criteria

* OAT treatment with phenprocoumon
* Lack of ability to handle the interface on the software used in the study (evaluated by the investigator present at the information meeting)
* Pregnancy
* Those with severe co-morbidities (e.g., creatinine \> 2.5, hepatic insufficiency, active malignancy, advanced physiological age, noncompliance risk, expected survival \<6 months), and physician or patient preference.

Primary outcomes:
measure: Time in therapeutic range
timeFrame: 6 months
Secondary outcomes:
measure: Log of the variance growth rate
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05967676: Psychological Readiness of Injured Athlete to Return to Sport
Official title: Turkish Adaptation, Validity and Reliability of the Psychological Readiness of Injured Athlete to Return to Sport (PRIA-RS) Questionnaire
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Athletic Injuries
Keywords: Validity
Reliability
Turkish Adaptation
Psychological Readiness
sports injury
Lead sponsor: Nigde Omer Halisdemir University
Sponsor class: OTHER
Collaborators: name: Gazi University
First posted: 2023-08-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Adaptation, validity and reliability
Primary purpose: DIAGNOSTIC

Brief summary: Clinicians are recommended to assess athletes during the rehabilitation phase to identify athletes with potentially maladaptive psychological responses to injury. Therefore, the Psychological Readiness of Injured Athlete to Return to Sport (PRIA-RS) questionnaire was developed to assess the athlete's psychological readiness to return to sport. The aim of this study was to adapt the PRIA-RS questionnaire into Turkish and to establish its validity and reliability. Serial approach method will be used while translating the questionnaire into Turkish. In order to evaluate the validity of PRIA-RS, The Re-injury Anxiety Inventory and Tampa Kinesiophobia Scale will be applied to the participants.


Eligibility criteria: Inclusion Criteria:

* athletes who have missed at least 2 months of training due to injury
* having an upper, lower extremity or spine injury

Exclusion Criteria:

* having a psychological disorder
* regular use of psychiatric medication

Primary outcomes:
measure: Psychological Readiness of Injured Athlete to Return to Sport (PRIA-RS)
timeFrame: Baseline
measure: Re-injury Anxiety Inventory (RAI):
timeFrame: Baseline
measure: Tampa kinesiophobia scale (TKS)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
state: Çankaya
Study officials:
References:
Clinical trial NCT05598476: Effect of Chest Compression on Respiratory Mechanics in ARDS Patients
Official title: Effect of Chest Compression on Respiratory Mechanics in ARDS Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ARDS, Human
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-10-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult ARDS patients under invasive mechanical ventilation

Brief summary: In some ARDS patients, a mild chest compression (5 kg) improves lung compliance.

We aim to determine wether such an improvement is due to a better recruitment or to a reduction of overdistension


Eligibility criteria: Inclusion Criteria:

* ARDS (Berlin definition)
* Age \>18y
* under invasive mechanical ventilation

Exclusion Criteria:

* people protected by the law

Primary outcomes:
measure: respiratory mechanics
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: